The Campbell group is working to understand the genetic transcription cycle of Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis, the leading cause of death by an infectious agent. This will lead to a better understanding of mycobacterial virulence for the development of new and improved therapeutics, including those that will be effective against drug-resistant strains of Mtb.
New antimicrobial therapies are essential to combating the global health crisis caused by tuberculosis (TB): Approximately one third of the world’s population is infected, and drug-resistant Mycobacterium tuberculosis (Mtb) strains are increasing.
The Campbell group is investigating mycobacterial RNA polymerase (RNAP), an enzyme responsible for bacterial transcription and a proven, effective target of antimicrobials. Using cryo-electron microscopy and other tools, she is working to reveal the mechanisms of RNAP and the molecular interactions between RNAP and its inhibitors. In a similar line of research, she is studying the atomic-level interactions between new and existing inhibitors and the SARS-CoV-2 transcription/replication machinery, work that could aid the design of novel drugs for COVID-19. Overall, her goal is to provide structural and functional insights into the nature of these pathogens to guide drug discovery and optimization.
